Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Receives Consensus Recommendation of "Hold" from Analysts

Key Points

• Analyst consensus: Eleven analysts give Immunocore an average rating of "Hold" (1 sell, 4 hold, 6 buy) with an average one-year price target of $60.89.
• Financials and insider activity: IMCR opened near $29.30, has a $1.49 billion market cap, reported ($0.60) EPS last quarter and a negative PE of -41.86. Insiders have sold 19,137 shares (~$619k) in the past three months, including CEO Bahija Jallal reducing her stake by about 48%.

Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR - Get Free Report) has received an average rating of "Hold" from the eleven ratings firms that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and six have given a buy recommendation to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $60.8889.

A number of research firms have commented on IMCR. Needham & Company LLC lifted their target price on shares of Immunocore from $71.00 to $75.00 and gave the stock a "buy" rating in a report on Thursday, February 26th. Wall Street Zen lowered shares of Immunocore from a "buy" rating to a "hold" rating in a report on Saturday, January 31st. Zacks Research lowered shares of Immunocore from a "strong-buy" rating to a "hold" rating in a report on Wednesday, February 25th. HC Wainwright reaffirmed a "buy" rating and set a $100.00 target price on shares of Immunocore in a report on Monday, April 20th. Finally, UBS Group set a $55.00 target price on shares of Immunocore and gave the stock a "buy" rating in a report on Wednesday, January 7th.

Immunocore Price Performance

IMCR opened at $29.30 on Friday. The company has a fifty day moving average price of $31.40 and a two-hundred day moving average price of $33.53. The company has a debt-to-equity ratio of 1.03, a quick ratio of 4.01 and a current ratio of 4.04. Immunocore has a 52 week low of $27.44 and a 52 week high of $40.71. The firm has a market capitalization of $1.49 billion, a PE ratio of -41.86 and a beta of 0.83.

Immunocore (NASDAQ:IMCR - Get Free Report) last released its earnings results on Saturday, February 14th. The company reported ($0.60) EPS for the quarter. Immunocore had a negative return on equity of 9.20% and a negative net margin of 8.88%.The business had revenue of $104.48 million for the quarter. As a group, analysts anticipate that Immunocore will post -0.97 earnings per share for the current year.

Insider Transactions at Immunocore

In other news, CEO Bahija Jallal sold 11,474 shares of Immunocore stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $32.35, for a total transaction of $371,183.90. Following the transaction, the chief executive officer directly owned 12,343 shares of the company's stock, valued at $399,296.05. This trade represents a 48.18% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Leger Tina Amber St sold 1,000 shares of Immunocore stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $32.35, for a total transaction of $32,350.00. Following the transaction, the insider directly owned 1,119 shares in the company, valued at approximately $36,199.65. This represents a 47.19% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 19,137 shares of company stock valued at $619,082 over the last three months. 10.40% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Immunocore

Hedge funds and other institutional investors have recently made changes to their positions in the company. Leonteq Securities AG bought a new position in shares of Immunocore during the fourth quarter worth $30,000. GAMMA Investing LLC boosted its position in shares of Immunocore by 51.6% during the third quarter. GAMMA Investing LLC now owns 914 shares of the company's stock worth $33,000 after purchasing an additional 311 shares in the last quarter. Harbour Investments Inc. boosted its position in shares of Immunocore by 60.2% during the fourth quarter. Harbour Investments Inc. now owns 1,033 shares of the company's stock worth $36,000 after purchasing an additional 388 shares in the last quarter. Rockefeller Capital Management L.P. bought a new position in shares of Immunocore during the fourth quarter worth $47,000. Finally, Arax Advisory Partners boosted its position in shares of Immunocore by 302.9% during the fourth quarter. Arax Advisory Partners now owns 1,386 shares of the company's stock worth $48,000 after purchasing an additional 1,042 shares in the last quarter. 84.50% of the stock is owned by institutional investors.

Immunocore Company Profile

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body's own T‐cell response to treat cancer and infectious diseases. The company's proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company's most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.